- Home
- CTNM
as 11-15-2024 4:00pm EST
Stocks
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 453.0M | IPO Year: | 2024 |
| Target Price: | $29.25 | AVG Volume (30 days): | 74.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.27 - $22.00 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Contineum Therapeutics Inc. Class A Common Stock News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation
Business Wire
4 days ago
Contineum Therapeutics to Attend Upcoming Investor Conferences
Business Wire
11 days ago
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Simply Wall St.
a month ago
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%
Business Wire
3 months ago
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Business Wire
3 months ago
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Business Wire
4 months ago
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
Business Wire
5 months ago
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Compare CTNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. Class A Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.